

Identity:

Title: Prof.Dr.
Family Name(s): YILMAZ
First Name(s): Mehmet Birhan
Age: 50

Photo:

Application for the following position in the HFA Board or Nominating Committee:
Secretary

Place of work

If you work in multiple places, please provide the one where you spend the most time or that you consider to be your main place of practice.

Institute/organisation:	Dokuz Eylul University
Department:	Cardiology
Address:	Inciralti, Balcova
Post code / Zip:	35330
Country:	Turkiye

General Curriculum Vitae (500 words max)

Please also include your H index and top 5 to 10 publications in the last 5 years

I was born in İzmir in 1974. I graduated from Hacettepe University Faculty of English Medicine in 1998. After completing Cardiology fellowship in 2003, I was appointed as Associate Professor of Cardiology at the Department of Cardiology of Sivas Cumhuriyet University Faculty of Medicine in 2006. I visited Advanced Heart Disease Section of Brigham Women Hospital of Harvard University in 2007. Between 2009-2010, I visited INSERM U 942 at Lariboisiere Hospital of Paris Diderot University and participated research on heart failure as a post-doc fellow. I served as the President of Heart Failure WG of Turkish Society of Cardiology (2014-2016) and served in the executive board of Turkish Society of Cardiology between 2016 and 2018. I have more than 300 papers on SCI journals with an h index more than 50. I have led the first national heart failure research program (SELFIE-TR) and has been leading Turkish Research Team in Heart Failure (TREAT-HF) registries for more than 10 years. I am also founding member of national HF certification program. I serve as the governor-elect of ACC Istanbul Consortium Chapter (ACC-ICC) and the founder of Eurasian Heart Failure Society, which aims to deep dive into specific HF-related issues in the region along with collaboration and networking from the MENA region.

I am currently full-time professor at Dokuz Eylul University, Faculty of Medicine, Department of Cardiology, Izmir, Turkiye with a main focus on heart failure.

Top 5 to 10 publications in the last 5 years:

1: Celik A, Ural D, Sahin A, Colluoglu IT, Kanik EA, Ata N, Arugaslan E, Demir E, Ayvali MO, Ulgu MM, Temizhan A, Cavusoglu Y, Acar RD, Nalbantgil S, Asarcikli LD, Murat S, Birinci S, **Yilmaz MB**. Trends in heart failure between 2016 and 2022 in Türkiye (TRends-HF): a nationwide retrospective cohort study of 85 million individuals across entire population of all ages. Lancet Reg Health Eur. 2023 Sep 5;33:100723. doi: 10.1016/j.lanepe.2023.100723.

2: Abdelhamid M, Al Ghalayini K, Al-Humood K, Altun B, Arafah M, Bader F, Ibrahim M, Sabbour H, Shawky Elserafy A, Skouri H, **Yilmaz MB**. Regional expert opinion: Management of heart failure with preserved ejection fraction in the Middle East, North Africa and Turkey. ESC Heart Fail. 2023 Oct;10(5):2773-2787. doi: 10.1002/ehf2.14456. Epub 2023 Aug 2. PMID: 37530028;

3: Doehner W, Čelutkienė J, **Yilmaz MB**, Coats AJS. Heart failure and the heart-brain axis. QJM. 2023 Nov 24;116(11):897-902. doi: 10.1093/qjmed/hcad179. PMID:37481714.

4: Desai AS, Vaduganathan M, Cleland JG, Claggett BL, Barkoudah E, Finn P, McCausland FR, **Yilmaz MB**, Lefkowitz M, Shi V, Pfeffer MA, McMurray JJV, Solomon SD. Mode of Death in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF Trial. Circ Heart Fail. 2021 Dec;14(12):e008597. doi: 10.1161/CIRCHEARTFAILURE.121.008597.

5: Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, Adams KF, Anand I, Arias-Mendoza A, Biering-Sørensen T, Böhm M, Bonderman D, Cleland JGF, Corbalan R, Crespo-Leiro MG, Dahlström U, Echeverria LE, Fang JC, Filippatos G, Fonseca C, Goncalvesova E, Goudev AR, Howlett JG, Lanfear DE, Li J, Lund M, Macdonald P, Mareev V, Momomura SI, O'Meara E, Parkhomenko A, Ponikowski P, Ramirez FJA, Serpytis P, Sliwa K, Spinar J, Suter TM, Tomcsanyi J, Vandekerckhove H, Vinereanu D, Voors AA, **Yilmaz MB**, Zannad F, Sharpsten L, Legg JC, Varin C, Honarpour N, Abbasi SA, Malik FI, Kurtz CE; GALACTIC-HF Investigators. Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. N Engl J Med. 2021 Jan 14;384(2):105-116.

6: Harjola VP, Parissis J, Bauersachs J, Brunner-La Rocca HP, Bueno H, Čelutkienė J, Chioncel O, Coats AJS, Collins SP, de Boer RA, Filippatos G, Gayat E, Hill L, Laine M, Lassus J, Lommi J, Masip J, Mebazaa A, Metra M, Miró Ò, Mortara A, Mueller C, Mullens W, Peacock WF, Pentikäinen M, Piepoli MF, Polyzogopoulou E, Rudiger A, Ruschitzka F, Seferovic P, Sionis A, Teerlink JR, Thum T, Varpula M, Weinstein JM, **Yilmaz MB**. Acute coronary syndromes and acute heart failure: a diagnostic dilemma and high-risk combination. A statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2020 Aug;22(8):1298-1314. doi:10.1002/ejhf.1831.

7: **Yilmaz MB**, Aksakal E, Aksu U, Altay H, Nesligül Y, Çelik A, Akil MA, Bekar L, Vural MG, Çetin Güvenç R, Özer S, Ural D, Çavuşoğlu Y, Tokgözoğlu L. Snapshot evaluation of acute and chronic heart failure in real-life in Turkey: A follow-up data for mortality. Anatol J Cardiol. 2020 Feb;23(3):160-168. doi:10.14744/AnatolJCardiol.2019.87894.

8: Rørth R, Jhund PS, **Yilmaz MB**, Kristensen SL, Welsh P, Desai AS, Køber L, Prescott MF, Rouleau JL, Solomon SD, Swedberg K, Zile MR, Packer M, McMurray JJV. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction. Circ Heart Fail. 2020 Feb;13(2):e006541. doi: 10.1161/CIRCHEARTFAILURE.119.006541.

9: Maack C, Eschenhagen T, Hamdani N, Heinzl FR, Lyon AR, Manstein DJ, Metzger J, Papp Z, Tocchetti CG, **Yilmaz MB**, Anker SD, Balligand JL, Bauersachs J, Brutsaert D, Carrier L, Chlopicki S, Cleland JG, de Boer RA, Dietl A, Fischmeister R, Harjola VP, Heymans S, Hilfiker-Kleiner D, Holzmeister J, de Keulenaer G, Limongelli G, Linke WA, Lund LH, Masip J, Metra M, Mueller C, Pieske B, Ponikowski P, Ristić A, Ruschitzka F, Seferović PM, Skouri H, Zimmermann WH, Mebazaa A. Treatments targeting inotropy. Eur Heart J. 2019 Nov 21;40(44):3626-3644. doi: 10.1093/eurheartj/ehy600.

10: Doehner W, Ural D, Haeusler KG, Čelutkienė J, Bestetti R, Cavusoglu Y, Peña-Duque MA, Glavas D, Iacoviello M, Laufs U, Alvear RM, Mbakwem A, Piepoli MF, Rosen SD, Tsigoulis G, Vitale C, **Yilmaz MB**, Anker SD, Filippatos G, Seferovic P, Coats AJS, Ruschitzka F. Heart and brain interaction

in patients with heart failure: overview and proposal for a taxonomy. A position paper from the Study Group on Heart and Brain Interaction of the Heart Failure Association. Eur J Heart Fail. 2018 Feb;20(2):199-215. doi: 10.1002/ejhf.1100.

Describe previous experience within the HFA, ESC and/or your National Cardiac/ HF Society

150 words maximum

I served as a member (2010-2014) and the President of HF WG of Turkish Society of Cardiology (TSC, 2014-2016). Then, I served in the board of TSC as the secretary of the presidential duo of TSC between 2016 and 2018 and particularly in reorganization of administrative assignments, particularly just after coup attempt, which required good communication skills along with the ability to solve conflicts as smooth as possible. In my presidency, we have, first-time in the history of TSC, generated Heart Failure Roadmap of Turkiye and I have had a connecting role for Ministry of Health's (MoH) adoption of the roadmap. Of note, Ministry of Health accepts to implement HF Roadmap of Turkiye till 2030. Hence, I am a respected national KOL in the field of HF. I have worked in committees of HFA particularly in Acute HF and Registries & Atlas Committee and Study Group on Heart & Brain.

Why are you motivated to join the HFA Board or Nominating Committee?

150 words maximum

I am motivated to join the HFA Executive Board as the secretary as I believe that I am good at networking at different levels and good at strategic planning and policy development, I am skilled at planning business and operations including social media operations and I believe that I can act as a representative and spokesperson for the HFA under the supervision of presidential trio.

How will you combine your HFA position with your daily clinical/research workload?

80 words maximum

The HFA position is line with my daily clinical/research workload. However, my HF team (two junior academic staff along with two fellows) at the department can compensate the local workload as we have such planning a priori.